Viviane Silva

Mrs. Viviane Silva

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
AAAna Laura V. Alves
Ana Laura V. Alves
IGIzabela N. F. Gomes
Izabela N. F. Gomes
ACAdriana C. Carloni
Adriana C. Carloni
MRMarcela N. Rosa
Marcela N. Rosa
LSLuciane S. da Silva
Luciane S. da Silva
VSViviane Silva
Viviane Silva
Glioblastoma (GBM) is the highest-grade form of glioma, as well as one of the most aggressive types of cancer, exhibiting rapid cellular growth and highly invasive behavior. Despite significant advances in diagnosis and therapy in recent decades, the outcomes for high-grade gliomas (WHO grades III-IV) remain unfavorable, with a median overall survival time of 15–18 months. The concept of cancer stem cells (CSCs) has emerged and provided new insight into GBM resistance and management. CSCs can self-renew and initiate tumor growth and are also responsible for tumor cell heterogeneity and the induction of systemic immunosuppression. The idea that GBM resistance could be dependent on innate differences in the sensitivity of clonogenic glial stem cells (GSCs) to chemotherapeutic drugs/radiation prompted the scientific community to rethink the understanding of GBM growth and therapies directed at eliminating these cells or modulating their stemness. This review aims to describe major intrinsic and extrinsic mechanisms that mediate chemoradioresistant GSCs and therapies based on antineoplastic agents from natural sources, derivatives, and synthetics used alone or in synergistic combination with conventional treatment. We will also address ongoing clinical trials focused on these promising targets. Although the development of effective therapy for GBM remains a major challenge in molecular oncology, GSC knowledge can offer new directions for a promising future.

18 August 2011
Verified
Journal Article
Open access
VSViviane Silva
Viviane Silva
APAnna Polesskaya
Anna Polesskaya
TSThais A. Sousa
Thais A. Sousa
VCVani M. A. Correa
Vani M. A. Correa
NANayara Delgado Andre
Nayara Delgado Andre
FLFernando L. De Lucca
Fernando L. De Lucca
Purpose: The apoptosis of retinal neurons plays a critical role in the pathogenesis of diabetic retinopathy (DR), but the molecular mechanisms underlying this phenomenon remain unclear. The purpose of this study was to investigate the cellular localization and the expression of microRNA-29b (miR-29b) and its potential target PKR associated protein X (RAX), an activator of the pro-apoptotic RNA-dependent protein kinase (PKR) signaling pathway, in the retina of normal and diabetic rats. Methods: Retinas were obtained from normal and diabetic rats within 35 days after streptozotocin (STZ) injection. In silico analysis indicated that RAX is a potential target of miR-29b. The cellular localization of miR-29b and RAX was assessed by in situ hybridization and immunofluorescence, respectively. The expression levels of miR-29b and RAX mRNA were evaluated by quantitative reverse transcription PCR (qRT-PCR), and the expression of RAX protein was evaluated by western blot. A luciferase reporter assay and inhibition of endogenous RAX were performed to confirm whether RAX is a direct target of miR-29b as predicted by the in silico analysis. Results: We found that miR-29b and RAX are localized in the retinal ganglion cells (RGCs) and the cells of the inner nuclear layer (INL) of the retinas from normal and diabetic rats. Thus, the expression of miR-29b and RAX, as assessed in the retina by quantitative RT-PCR, reflects their expression in the RGCs and the cells of the INL. We also revealed that RAX protein is upregulated (more than twofold) at 3, 6, 16, and 22 days and downregulated (70%) at 35 days, whereas miR-29b is upregulated (more than threefold) at 28 and 35 days after STZ injection. We did not confirm the computational prediction that RAX is a direct target of miR-29b. Conclusions: Our results suggest that RAX expression may be indirectly regulated by miR-29b, and the upregulation of this miRNA at the early stage of STZ-induced diabetes may have a protective effect against the apoptosis of RGCs and cells of the INL by the pro-apoptotic RNA-dependent protein kinase (PKR) signaling pathway.

26 May 2017 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
TMTaciane Macedo
Taciane Macedo
RSRenato J. Silva-Oliveira
Renato J. Silva-Oliveira
VSViviane Silva
Viviane Silva
DVDaniel O. Vidal
Daniel O. Vidal
AEAdriane F. Evangelista
Adriane F. Evangelista
MMMarcia Marques
Marcia Marques
Breast cancer (BC) is a leading cause of cancer-associated mortality in females worldwide. MicroRNAs (miRNAs or miRs), a type of non‑coding RNA, have been reported to be important in the regulation of BC onset and progression. Several studies have implicated the role of miR‑183 and miR‑494 in different types of cancer. However, the biological functions of these miRNAs in BC remain largely unknown. In the present study, the expression of both miRNAs was assessed in the MDA-MB-231 and MDA‑MB‑468 BC cell lines. It was hypothesized that miR‑183 and miR‑494 serve an important role in regulating the expression of key genes associated with the metastatic phenotype of BC cells. To further understand their role, the expression of these miRNAs was restored in selected BC cell lines. Functional assays revealed that overexpression of miR‑183 or miR‑494 modulated the proliferation and migration of MDA‑MB‑231 and MDA‑MB‑468 cells in vitro. Additionally, retinoblastoma 1 (RB1) was identified to be a downstream target of both miRNAs by in silico analysis. Western blotting revealed that upregulation of miR‑183 was associated with downregulation of RB1 protein in MDA‑MB‑231 cells. In conclusion, the present results support the hypothesis that miR‑183 and miR‑494 serve a pivotal role in BC metastasis, and that miR‑183 may act as an oncogene by targeting RB1 protein in MDA‑MB‑231 cells.

22 June 2018 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
VSViviane Silva
Viviane Silva
MRMarcela N. Rosa
Marcela N. Rosa
VMVera Miranda-Gonçalves
Vera Miranda-Gonçalves
ACAngela Costa
Angela Costa
ATAline Tansini
Aline Tansini
RRRui M. Reis
Rui M. Reis

1 December 2018 in Toxicon
Verified
Journal Article
Closed access
SMSilvana Pinotti Muller
Silvana Pinotti Muller
VSViviane Silva
Viviane Silva
ASAna Vitória Pupo Silvestrini
Ana Vitória Pupo Silvestrini
LMLuana Henrique de Macedo
Luana Henrique de Macedo
GCGuilherme Ferreira Caetano
Guilherme Ferreira Caetano
MMMaurício V Mazzi
Maurício V Mazzi

26 February 2016 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
RSRenato José Silva-Oliveira
Renato José Silva-Oliveira
VSViviane Silva
Viviane Silva
Olga MartinhoOlga Martinho
Olga Martinho
ACAdriana Cruvinel-Carloni
Adriana Cruvinel-Carloni
MMMatias Eliseo Melendez
Matias Eliseo Melendez
RRRui M. Reis
Rui M. Reis